BioCentury
ARTICLE | Company News

FDA committee to discuss AZ's gout treatment

August 19, 2015 12:51 AM UTC

FDA's Arthritis Advisory Committee will meet on Oct. 23 to discuss an NDA for lesinurad in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout. Ardea Biosciences Inc. submitted the NDA; AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired Ardea in 2012 for $1.3 billion. ...